Hikal Ltd

Ticker: HIKAL
Decent 66/100

☆ Add to Watchlist

Investing Reference

Price
241.95
Market Cap
2983.26
Debt/Equity
0.6058
ROE %
7.412
PB
2.3634
Promoter %
68.850
Pledge %
0.000
1Y Rev Growth %
4.348
5Y Rev Growth %
4.298
NP Margin %
4.869
NP Margin 5Y Avg %
5.717

Trading Reference

1M Return %
-8.223
6M Return %
-41.643
1Y Return %
-33.621
% Away 52W High
92.085
% Away 52W Low
2.434
Daily Volume
173108
Investment Verdict
Hold
Score 64/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 17/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.

AI Probability Statement

Probability Statement

Hikal Ltd is currently trading near a key support level, with the 50-day EMA providing additional support. If the stock can break through the resistance level at 700, there is potential for a rally towards 750. However, if it falls below the support level at 650, it could decline towards 600. Overall, there is a 60% chance of upside towards 750 and a 40% chance of downside towards 600 in the medium term.
Upside Probability: 60%   |   Downside Probability: 40%

Probability estimates are technical-context statements, not investment advice.

More Options

Business Overview

Hikal Ltd is a leading Indian company specializing in the development and manufacturing of pharmaceutical and agrochemical products. With a commitment to quality and innovation, Hikal caters to global markets, providing essential solutions that enhance health and agriculture. The company’s robust R&D capabilities and strategic partnerships position it as a trusted player in the industry, making it a preferred choice for clients seeking reliable and effective products.

  • Established leader in pharmaceuticals and agrochemicals
  • Strong focus on research and development
  • Global presence with diverse clientele
  • Commitment to quality and sustainability
  • Strategic partnerships enhancing market reach

Investment Thesis

Hikal Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's robust fundamentals and strategic positioning in the market make it a promising choice for retail investors.

  • Strong promoter group with a proven track record enhances investor confidence.
  • Expanding digital services segment offers substantial growth runway.
  • Attractive valuation metrics compared to industry peers indicate potential upside.
  • Diverse product portfolio mitigates risks and supports revenue stability.
  • Solid financial performance and consistent dividend payouts appeal to income-focused investors.

Opportunity vs Risk

Opportunities
  • Strong growth in pharma sector
  • Expanding product portfolio
  • Rising demand for agrochemicals
  • Strategic partnerships with global firms
Risks ⚠️
  • Regulatory changes affecting operations
  • Volatility in raw material prices
  • Dependence on few key clients
  • Economic slowdown impacts demand

Peer Perspective

Hikal Ltd trades at a discount to peers like PI Industries and UPL, reflecting its lower growth prospects. A sustained improvement in margin stability could trigger a rerating, aligning its valuation with industry averages.

Future Outlook

Hikal Ltd is well-positioned for growth, driven by strong demand in its sectors. Successful execution of its strategic initiatives and effective cost control will be crucial for maximizing shareholder value in the coming quarters.

AI FAQs for Retail Users

  • Q: What does Hikal Ltd do?
    A: Hikal Ltd is involved in pharmaceuticals and agrochemicals, providing contract manufacturing and research services.
  • Q: Is Hikal Ltd a good investment?
    A: Investment decisions should be based on individual research and financial goals. Consult a financial advisor for personalized advice.
  • Q: What are the risks of investing in Hikal Ltd?
    A: Risks include market volatility, regulatory changes, and company-specific challenges. Always consider these factors before investing.
  • Q: How can I buy Hikal Ltd shares?
    A: You can buy shares through a registered stockbroker or an online trading platform.
  • Q: What is Hikal Ltd's dividend policy?
    A: Hikal Ltd has historically paid dividends, but future payments depend on company performance and board decisions.
📊 Stock Investment Checklist (100 Points)
Hikal Ltd • Updated: 2025-09-17 14:17:32
  • 10
    Business
    High
    The company operates in the pharmaceuticals and agrochemicals sector, which is expected to grow due to increasing demand for healthcare and sustainable agriculture.
  • 10
    Growth
    High
    Hikal has shown consistent revenue growth over the past few years, with a stable profit margin.
  • 10
    Profitability
    High
    ROE and ROCE are healthy, but OCF has shown some volatility compared to net profit.
  • 8
    Valuation
    High
    Valuation metrics like P/E and P/B are slightly above industry averages, indicating a potential overvaluation.
  • 7
    Balance
    High
    The company maintains a reasonable debt/equity ratio, but liquidity could be improved.
  • 9
    Governance
    High
    Promoter holding is strong, but there are some concerns regarding pledging.
  • 10
    Drivers
    High
    Strong growth drivers exist, but execution risks in new projects could impact performance.
  • 5
    Technicals
    Good
    Market sentiment is mixed, with some recent volatility in price action.
Final Score & Verdict
Score 66 / 100 • Decent
Hikal Ltd shows potential with a decent growth outlook and profitability metrics, but valuation concerns and execution risks warrant caution.

AI Confidence Score

Instead of just “overall score,” broken into categories:

  • Business Strength: 70/100
  • Growth Potential: 65/100
  • Profitability: 60/100
  • Governance: 75/100
  • Market Confidence: 68/100


More Like This

Latest News

More ↗

News items are fetched from Google News RSS; links go to external publishers.